Seladelpar for bile duct damage after liver transplant
Part of Digestive system clinical trials.
This trial tests a drug called seladelpar for people who have developed bile duct damage (ischemic cholangiopathy) after a liver transplant. The drug may help improve liver function and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 79 years old.
- You have had a liver transplant and within the past year developed bile duct narrowing or damage (confirmed by imaging).
- Your liver blood tests show signs of bile flow problems (elevated ALP and GGT).
- You have not been hospitalized in the last 2 weeks.
- You are not pregnant or breastfeeding, and you are not taking certain medications (like cyclosporine or fenofibrate) or other investigational drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an endoscopic (camera-based) approach to treat bile duct narrowing that happens after a liver transplant. It may help improve bile flow and liver blood test results when the narrowing is in the bile duct area near where the liver’s bile ducts split.
This study is testing a special temporary stent that breaks down over time to help open a narrowed bile duct after a liver transplant. It may help avoid long-term plastic stents or additional surgery.
This study tests whether a type of stem cell, given during liver transplant surgery, can help prevent bile duct complications. It is for people receiving a liver from a living donor.
This trial tests whether fenofibrate can prevent primary sclerosing cholangitis (PSC) from coming back after a liver transplant. It is for adults who had a liver transplant for PSC between 1 and 7 years ago and have certain risk factors.
This trial tests a medicine called seladelpar for people with primary biliary cholangitis (PBC) and cirrhosis, a form of liver scarring. The goal is to see if it can help improve liver health and reduce symptoms.
This study collects real-life data from patients with primary biliary cirrhosis who are already taking seladelpar, to better understand how the drug works outside of clinical trials. It may help improve future treatment for PBC.
Hear when a new Liver Transplant; Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.